Key Inclusion Criteria:~* The participant must have confirmed amyloid beta pathology by cerebrospinal fluid
(CSF) or amyloid PET~* Must have history of subjective memory decline with gradual onset and slow progression
over the 6 months before Screening, confirmed by study partner~* The participant must have 1 informant/care
partner who, in the Investigator's opinion, has frequent and sufficient contact with the participant (at least
10 hours/week in person or by phone) as to be able to provide accurate information about the participant's
cognitive and functional abilities over time~* Must meet all of the following clinical criteria for MCI due to
Alzheimer's disease or mild Alzheimer's disease according to National Institute on Aging and Alzheimer's
Association (NIA-AA) criteria~ 1. Have an MMSE score between 22 and 30 inclusive~ 2. Have a CDR memory score
>0.5~ 3. Have a Clinical Dementia Rating Scale Global Score (CDR-GS) of 0.5 or 1.0~ 4. Have a Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS) score of 85 or lower indicative of objective
cognitive impairment~* Apart from a clinical diagnosis of early Alzheimer's disease, the participant must be in
good health as determined by the Investigator based on medical history and screening assessments~* Must consent
to apolipoprotein E (ApoE) genotyping. (Note: Participants are not required to be ApoE Îµ4 carriers)~Key
